BioSpace News Archive

Aptevo Therapeutics Inc. and Alligator Bioscience provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen.

Ventus Therapeutics, a biopharmaceutical company with proprietary technologies for structure-enabled small-molecule drug discovery that is developing medicines targeting the innate immune system, announced that it has been selected as one of 10 Start-Ups to Watch by Chemical & Engineering News.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of sys

Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. (“Aptevo”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced receipt of the Clinical Trial Authorization (CTA) in the UK for the Company’s Cancer Appetite Recovery Study (CAReS).

Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill & Melinda Gates Medical Research Institute, to the Company’s Board of Directors (the “Board”).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript detailing the study design and methodology for its global Phase 3 INNO2VATE program in Nephrology Dialysis Transplantation (NDT),

Global biotherapeutics leader CSL Behring announced a community partnership with six Urban League affiliates across the U.S., starting with the Urban League of Philadelphia.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce topline results from the Company’s partnership with the Icahn School of Medicine at Mount Sinai, New York (“Icahn School of Medicine”)

In an unprecedented collaboration designed to speed research advances, Duchenne UK, the Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) have announced a joint grant of $686,500 to Dr. William Evans (principal investigators